GLRA
ICPT

Gerald L. Ray & Associates’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Gerald L. Ray & Associates’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,550
Closed -$1.76M – 335
2017
Q2 		$1.76M Hold
14,550
– – 0.23% 101
2017
Q1 		$1.65M Buy
14,550
+2,300
+19% +$269K 0.23% 101
2016
Q4 		$1.33M Buy
12,250
+7,210
+143% +$859K 0.19% 113
2016
Q3 		$830K Buy
5,040
+1,410
+39% +$222K 0.12% 150
2016
Q2 		$518K Buy
+3,630
New +$529K 0.08% 196

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Gerald L. Ray & Associates's ICPT Position: Q3 2017 in Review

Gerald L. Ray & Associates sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 14,550 shares — an estimated $1.76M sold.

Gerald L. Ray & Associates first reported a position in ICPT in Q2 2016 and held it in 5 quarters. The position peaked at $1.76M in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

  • Gerald L. Ray & Associates reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Gerald L. Ray & Associates sold 14,550 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.76M.
  • Gerald L. Ray & Associates first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 5 quarters.
  • Gerald L. Ray & Associates's Intercept Pharmaceuticals, Inc. position peaked at $1.76M in Q2 2017.
  • 155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.